Institute of Haematology
The Institute of Haematology Research Unit is a leader in both clinical and laboratory research spanning malignant and non-malignant haematology. Our clinical trials unit has been very active in multiple diseases over many years, investigating and making available many state-of-the-art agents and protocols to our patients. Our laboratory research unit has concentrated on basic research into the immunology and molecular pathophysiology of myeloma, the molecular basis and monitoring of acute promyelocytic leukaemia and myeloproliferative diseases, the immunological aspects of transplantation and immunotherapy, and the pathophysiology and laboratory assays to monitor the treatment of clotting disorders.
I. Clinical Research:
RPA Haematology has been highly active in clinical trials over many years, and is one of the highest recruiters of many Australian and multi-national clinical trials in Haematology. Key members of our staff have taken a leadership role as principal investigators in trials in myeloma, leukaemia, the haemoglobinopathies and haemostasis.
Our clinical trial activity covers a wide portfolio - myeloma in all stages of disease, acute myeloid and lymphoblastic leukaemia, acute promyelocytic leukaemia, numerous subtypes of lymphoma (eg. diffuse large B cell lymphoma, follicular lymphoma, Hodgkin lymphoma, and primary CNS lymphoma), chronic lymphocytic leukaemia, myelofibrosis, myelodysplasia, allogeneic stem cell transplantation, haemophilia, haemoglobinopathies and iron overload.
In the last 3 years we have had 37 active clinical trials, screened 521 and enrolled 263 patients, not including patients enrolled more than 2 years ago who are still being followed up. The majority of the collaborative group trials are carried out under the auspices of the Australasian Leukaemia and Lymphoma Group, of which the RPA Haematology team are key members.
Main areas of interest in our group are myeloma, acute promyelocytic leukaemia and blood & marrow transplantation, the haemoglobinopathies and clotting disorders, for which our unit has been considered the leading sites of investigative studies, with members of our staff being the instigator of national trials - current trials include Prof Joy Ho's ALLG MM16 trial, and Prof Harry Iland's recently completed ALLG APML4, which both employed novel state-of-the-art compounds and strategies.
The APML4 trial has revolutionized the care and outcomes for patients with APL by demonstrating that arsenic trioxide can be successfully incorporated into the standard ATRA + chemotherapy backbone for frontline therapy. The final analysis of the APML4 trial was selected for oral presentation at the American Society of Hematology Annual Scientific meeting in December 2014, and was published in Lancet Haematology in 2015. The longer follow-up demonstrated significantly improved overall survival compared with Prof Iland's previous ALLG APML3 trial that did not include arsenic. APML4 has also proved to be practice-changing at an international level, as demonstrated by its inclusion in the US National Comprehensive Cancer Network's recommendations for the treatment of high-risk APL. Data from the APML4 trial was also instrumental in the registration of arsenic trioxide by the TGA for front-line therapy of APL, and for its corresponding PBS listing. Prof Iland's forthcoming APML5 trial is a phase I pharmacokinetic study of a novel oral arsenic formulation, and has already generated requests for international collaboration from Memorial Sloan Kettering Cancer Center (New York), Robert H. Lurie Comprehensive Cancer Center (Chicago), and Princess Margaret Hospital (Toronto).
In myeloma, Prof PJ Ho is the Principal Investigator (PI) of the ALLG MM16 trial, a multicentre ALLG study which investigates the early kinetics of serum free light chains as a predictor of reversal of renal impairment, a key adverse prognostic factor in myeloma, utilising a novel proteasome inhibitor Carfilzomib. RPA has been a key site in major myeloma trials in the newest agents and treatment protocols, including carfilzomib, ixazomib, daratumumab as an immunotherapy being a first-in-class antibody against CD38, pomalidomide, and current work is being undertaken to further expand our trial portfolio including new antibodies and bcl-2 inhibitors. Prof Ho and Joshua are active members of the International Myeloma Working Group (IMWG).
The RPAH Myeloma Group was the first NSW site to join the national Myeloma and related Diseases Registry (MRDR) and is the highest recruiting NSW site.
RPA Haematology is one of only 2 Australian sites selected for the current multinational trial on Chimeric Antigen Receptor (CAR)-T cells in diffuse large B cell lymphoma. This study, with Prof Ho as PI, represents an extremely important achievement in the development of our unit. Precise and careful coordination between multiple sections of our department ranging from apheresis, cell therapies and clinical in-patient and out-patient staff, as well as cooperation with emergency and ICU colleagues have been established to ensure successful conduct of this seminal trial, bringing a ground-breaking therapy to Australia. It is hoped that experience in this first trial will be extended in the near future, to be applied to other lymphoproliferative diseases and other haematological malignancies.
The RPAH Blood and Bone Marrow Transplantation (BMT) group, led by Prof John Gibson and A/Prof Stephen Larsen, has also been highly active in clinical trials. In collaboration with other NSW allogeneic BMT centres we are key participants of a clinical trial assessing the safety and efficacy of a myeloablative conditioning regimen for haploidentical allogeneic transplants, as well as an important project that aims to standardise conditioning regimens for allogeneic BMT in acute myeloid leukaemia patients. We are also participating in an ALLG trial exploring reduced intensity conditioning in patients with acute myeloid leukaemia between the ages of 51 and 70, and in a large clinical project exploring long-term follow-up care of BMT patients. Our unit is a major contributor to both national and international registries. Prof Gibson is a member of 3 scientific sub-committees - in myeloma, lymphoma, and graft manipulation. In addition to ongoing accreditation by the Australian Blood and Marrow Donor Registry (ABMDR) and the Centre for International Blood and Marrow research CIBMTR) our transplant service is the only NSW service accredited by the Therapeutic Good Administration (TGA).
In the 'non-malignant' aspects of haematology, our Unit has been an instigator of national clinical trials on the impact of iron overload on haematological disease, including not only the haemoglobinopathies but also the myelodysplastic syndromes and myeloproliferative diseases. Firstly a multi-centre clinical study led by Prof Ho on the effect of an oral iron chelator on cardiac iron, assessed by state-of-the-art technology of cardiac MRI with T2* quantitation in conjunction with MRI assessment of liver iron was conducted and presented at both ASH and EHA meetings, and now accepted for publication in European Journal of Hematology. Secondly and more recently, a multi-centre national epidemiological study on the prevalence of cardiac and hepatic iron load in transfusion-dependent anaemias and non-transfusion-dependent thalassaemia (NTDT) including transfusion-dependent malignant diseases was led by Prof Ho. It established the impact of iron toxicity on disease course, and was a major achievement in the integration of improved disease monitoring by cardiac and liver MRI monitoring with improved treatment using oral iron chelation. The findings were selected for oral presentation at the American Society of Hematology Annual Scientific meeting in December 2015.
In haemophilia and the clotting disorders, amongst many clinical studies in which Drs Dunkley and Khoo are participating in, utilising state-of-the-art products in patients with clotting deficiencies, Dr Khoo is conducting an investigator initiated field study in Australian haemophilia laboratories to review FVIII measurements for the new extended half-life FVIII product.
Our unit is also a pioneer in promoting research in haematological nursing, with specialty nurses conducting research in myeloma, transplantation and quality of life. Tracy King and Sally Taylor have conducted studies on quality of life and toxicity management in myeloma care, resulting in several abstract presentations in HAA meeting, including an award at the Haematology Society HAA Scientific Meeting. Katrina Wilczek is conducting research in long-term follow-up of stem cell transplant patients. Tracy King is the only non-American member of the International Myeloma Foundation Nurse Leadership Board.
II. Laboratory and translational research:
In many diseases our work in the laboratory is highly complementary to our clinical research and our very busy clinical practice. Our unit has been heavily involved in the investigation of the immune and molecular pathophysiology of myeloma, and is widely considered an Australian pioneer in examining the immunological basis of myeloma, with enormous impact on current developments in immunotherapy. Recent work has focused on the precise phenotype of clonal T cells, defining the mode of telomere-independent senescence, with likely implications on the use of CAR-T therapy and other strategies of immunotherapy in myeloma. Continuing work on the dysfunctional immune system, dysregulated signaling pathways, T regulatory cells, trogocytosis, checkpoint inhibition, long-term survivors and targets for novel therapies including cancer stem cells will have significant impact on new therapies. Investigations into the molecular basis of myeloma has led to new insights in the role of FGFR3 a key candidate gene in the t(4;14) translocation, and more recent work established digital PCR in the detection of minimal residual disease, and the role of other candidate gene expression on disease behaviour. Through the years, our work has revealed the multi-faceted nature of myeloma pathogenesis. For example in the ALLG MM6 study investigating the role of thalidomide in consolidation after autologous transplantation, our work in both immunological and molecular aspects revealed the importance of T cell clones as well as the expression of one of the key candidate genes FGFR3 in the translocation t(4;14) in predicting disease outcome.
The Molecular Haematology Laboratory provides a comprehensive diagnostic service for the detection and quantitation of gene mutations in patients with myeloid malignancies. The range of tests is continuously being expanded as knowledge about the pathogenesis of leukaemias and myeloproliferative disorders increases, and this activity has been accelerated by the recruitment of a Fellow in Molecular Haematology (Dr Derek McCulloch) in 2016. Members of the Molecular Laboratory have utilised their expertise to identify novel variants of acute promyelocytic leukaemia (the PRKAR1A-RARA rearrangement - Dr Alberto Catalano) and core binding factor acute myeloid leukaemia (the type J variant of the CBFB-MYH11 rearrangement - Ms Francisca Supple). Patients with non-malignant disorders are also studied, and this work has led to the recognition of a novel XK gene mutation in a patient with the McLeod syndrome (Dr Shane Supple). The Molecular Laboratory also actively supports clinical trial research by providing critical molecular data for national and international trials in AML (the ALLG M16 trial in FLT3-positive AML) and APL (our laboratory is the only Australian facility that is accredited to perform molecular testing for the US Children's Oncology Group trial in paediatric APL).
In blood and marrow transplantation, in collaboration with Professor Derek Hart we have been exploring the kinetics of different cell populations, especially dendritic cells and regulatory T cells, in patients being treated with extra-corporeal photopheresis for the treatment of chronic graft versus host disease. We are also involved with a translational project exploring the use of a monoclonal antibody to CD83 to prevent graft versus host disease
- Elucidation of the mechanisms of T cell dysfunction or senescence in myeloma - Identification of novel targets and key factors in checkpoint blockade in myeloma; - Characterisation of the mechanisms of tumour-induced inhibition of clonal T cell expansions in multiple myeloma -Suen H, Brown R, Yang S, Weatherburn C, Ho PJ, Woodland N, Nassif N, Barbaro P, Bryant C, Hart D, Gibson J, Joshua D (2016). Multiple myeloma causes clonal T cell immunosenescence: Identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia 2016; 30(8):1716-24. - Suen H, Brown R, Yang S, Ho PJ, Gibson J, Joshua D. The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study. Leukemia. 2015;29(7):1621-2.
- Prof H Iland was principal investigator for APML4, the final analysis of which was published in Lancet Haematology. - APML4 trial combined ATRA, arsenic trioxide and idarubicin for the management of APL, and achieved outstanding success with 95% complete remission, 95% disease-free survival at 5 years, and 94% overall survival at 5 years. - The APML4 protocol is now recommended by the US National Comprehensive Cancer Network, and also by a panel of Canadian APL experts, for the treatment of high-risk APL. - APML4 results led to approval by the TGA for the use of arsenic trioxide as initial therapy in APL, ahead of both the European and the US regulatory authorities (where arsenic trioxide is still not approved for front-line use). The PBAC has also recently extended PBS-funding for arsenic trioxide-based therapy in the initial therapy of APL, and that approval was based in part on APML4 data. - Iland HJ, Collins M, Bradstock K, Supple SG, Catalano A, Hertzberg M, Browett P, Grigg A, Firkin F, Campbell LJ, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF for the Australasian Leukaemia and Lymphoma Group. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol 2015; 2(9):e357-66.
- Prof J Ho was principal investigator of (a) epidemiological study of iron overload in transfusion dependent anaemias and non-transfusion dependent thalassaemia, selected for oral presentation at American Society of Haematology 2015. The study provided new and important insights into the impact of iron toxicity on disease course, and was a major achievement in the integration of improved disease monitoring by cardiac and liver MRI monitoring with improved treatment using oral iron chelation - Ho PJ, Hiwase D, Ramakrishna R, Viiala N, Ross D, Zor E, Gervasio O, Bowden DK. Prevalence of cardiac and hepatic siderosis in Australian patients with transfusion-dependent anemias or non-transfusion-dependent thalassemia as assessed by MRI (the TIMES study). Oral presentation at American Society of Hematology Annual Scientific meeting, 2015. Blood (2015) 126:540 and (b) multi-centre study on the effect of an oral iron chelator on cardiac iron in transfusion-dependent diseases, a very important factor in mortality in patients with the haemoglobinopathies, assessed by state-of-the-art technology of cardiac MRI with T2* quantitation in conjunction with MRI assessment of liver iron, accepted for publication: - Ho PJ, Tay L, Teo J, Marlton P, Grigg A, St Pierre T, Brown G, Badcock C, Traficante R, Gervasio OL, Bowden DK. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study). Eur J Hematol (2016), in press.
- Gene therapy of 2 thalassaemia major patients (PJ Ho, J Rasko), RPA Haematology and another site in Thailand being the only non-American clinical sites, enrolling 2 out of the total 13 patients reported in this international gene therapy trial utilising a lentiviral vector - oral presentation at American Society of Hematology 2015 - Walters MC, Rasko J, Hongeng S, Kwiatkowski J, Schiller GJ, Kletzel M, Ho PJ, Vichinsky E, von Kalle C, Cavazzana M, Philippe Leboulch, Petrusich A, Soni S, Thompson AA. Update of Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral Beta AT87Q-Globin Vector (LentiGlobin BB305 Drug Product). Blood 126:201.
- Only 1 of 2 Australian sites in ground-breaking chimeric antigen receptor T cells treatment in diffuse large B cell lymphoma, 7 patients on trial to date (as of August 2016)
- Harry Iland - awarded Robert Pitney Travelling Fellow of the HSANZ for 2015-2016.
- Harry Iland - awarded the Carl de Gruchy Orator for HSANZ, to be presented in 2016.
- Tracy King - Recognition of distinguished service to the myeloma community as an International Affiliate of the International Myeloma Foundation Nurse Leadership Board, 2016
- Prof P. Joy Ho (Director of Research)
- Prof John Gibson (Head of Department)
- A/Prof Christina Brown
- Dr Ross Brown
- Dr Christian Bryant
- Dr Alberto Catalano
- Dr Scott Dunkley
- Dr Jenny Hsu
- Prof Harry Iland
- Ms Alana Johnson
- Prof Doug Joshua
- Dr Liane Khoo
- A/Prof Stephen Larsen
- Dr Derek McCulloch
- Dr Dimitrii Minchenko
- Ms Cheryl Paul
- Ms Hayley Suen
- Ms Francisca Supple
- Dr Shane Supple
- Dr Claire Weatherburn
- Ms Shihong Yang
Clinical Trial Coordinators:
- Ms Elizabeth Tucker
- Ms Alexie Soulos
- Ms Flavia Li
- Prof Derek Hart
- Prof John Rasko
Haematology Specialty Nurses:
Higher Degree Students:
- Tracy King - myeloma
- Louise Kerr - transplantation
- Sally Taylor - transplantation
- Katrina Wilczek - transplantation
- Stephen Matthews - haemophilia and thalassaemia/sickle cell disease
- Clare Waite - haemophilia and thalassaemia/sickle cell disease
- Hayley Suen
- Geoff Kershaw
- Claire Weatherburn
- Daniel Orellana
- Bernadette Blayney
- Mark Langshaw
- Katrina Wilczek
Publications and Presentations
- International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski RZ, Powles R, Vesole DH, Garderet L, Einsele H, Palumbo A, Cavo M, Richardson PG, Moreau P, San Miguel J, Rajkumar SV, Durie BG, Terpos E .J Clin Oncol. 2016 Mar 14. pii: JCO650044
- High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.Nath CE, Trotman J, Tiley C, Presgrave P, Joshua D, Kerridge I, Kwan YL, Gurney H, McLachlan AJ, Earl JW, Nivison-Smith I, Zeng L, Shaw PJ. Br J Clin Pharmacol. 2016 Feb 15
- A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset. Bryant C, Fromm PD, Kupresanin F, Clark G, Lee K, Clarke C, Silveira PA, Suen H, Brown R, Newman E, Cunningham I, Ho PJ, Gibson J, Bradstock K, Joshua D, Hart DN. Immunol Cell Biol. 2016 Jan 21.
- Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim CS, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, McCarthy P, Dimopoulos M, Moreau P, Orlowski RZ, Miguel JS, Anderson KC, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG. Leukemia. 2015 Dec 29
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR investigators Lancet Oncol. 2016 Jan;17(1):27-38. 68]
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. N Engl J Med. 2016 Apr 28;374(17):1621-34.
- Multiple myeloma causes clonal T cell immunosenescence: Identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Suen H, Brown R, Yang S, Weatherburn C, Ho PJ, Woodland N, Nassif N, Barbaro P, Bryant C, Hart D, Gibson J, Joshua D. Leukemia. 2016 Apr 22
- Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Moreau P, Joshua D, Chng WJ, Palumbo A, Goldschmidt H, Hájek R, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Dimopoulos MA.
Leukemia. 2016 Aug 5.
- CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses. Fromm PD, Papadimitrious MS, Hsu JL, Van Kooten Losio N, Verma ND, Lo TH, Silveira PA, Bryant CE, Turtle CJ, Prue RL, Vukovic P, Munster DJ, Nagasaki T, Barnard RT, Mahler SM, Anguille SA, Berneman Z, Horvath LG, Bradstock KF, Joshua DE, Clark GJ, Hart DN. Oncoimmunology. 2016 May 5;5(6):e1168555.
- The T Cell in Myeloma - Douglas Joshua, Hayley Suen, Ross Brown, Christian Bryant, P Joy Ho, Derek Hart, John Gibson Clinical Lymphoma Myeloma & Leukemia : 2016 ; Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):537-542.
- Human plasma-derived FVIII/VWD concentrate (Biostate): a review of experimental and clinical pharmacokinetic, efficacy and safety data. Harper P, Favaloro EJ, Curtin J, Barnes C, Dunkley S. Drugs Context. 2016 Apr 8; 5: 212-292.
- Mohamed M, Sharma S, Supple SG, Iland H. Atypical presentation of therapy-related acute promyelocytic leukaemia with marrow fibrosis. Pathology 2016; 48(3):286-288.
- Ho PJ, Bajel A, Burbury K, Dunlop L, Durrant S, Forsyth C, Perkins AC, Ross DM. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis. Intern Med J. 2017 Mar;47(3):262-268. doi: 10.1111/imj.13341. PubMed PMID: 28260257.
- Joshua D, Suen H, Brown R, Bryant C, Ho PJ, Hart D, Gibson J. The T Cell in Myeloma. Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):537-542. doi:
10.1016/j.clml.2016.08.003. Epub 2016 Aug 10. PubMed PMID: 27601001.
- Ho PJ, Tay L, Teo J, Marlton P, Grigg A, St Pierre T, Brown G, Badcock CA, Traficante R, Gervasio OL, Bowden DK. Cardiac iron load and function in
transfused patients treated with deferasirox (the MILE study). Eur J Haematol. 2017 Feb;98(2):97-105. doi: 10.1111/ejh.12793. Epub 2016 Sep 20. PubMed PMID: 27537786.
- Ho PJ, Siordia JA. Dabigatran approaching the realm of heparin-induced
thrombocytopenia. Blood Res. 2016 Jun;51(2):77-87. doi: 10.5045/br.2016.51.2.77.Epub 2016 Jun 23. Review. PubMed PMID: 27382551; PubMed Central PMCID:PMC4931941.
- Picón A, Lehmann CS, Bostedt C, Rudenko A, Marinelli A, Osipov T, Rolles D,Berrah N, Bomme C, Bucher M, Doumy G, Erk B, Ferguson KR, Gorkhover T, Ho PJ,Kanter EP, Krässig B, Krzywinski J, Lutman AA, March AM, Moonshiram D, Ray D,Young L, Pratt ST, Southworth SH. Hetero-site-specific X-ray pump-probe spectroscopy for femtosecond intramolecular dynamics. Nat Commun. 2016 May 23;7:11652. doi: 10.1038/ncomms11652. PubMed PMID: 27212390; PubMed Central PMCID: PMC4879250.
- Suen H, Brown R, Yang S, Weatherburn C, Ho PJ, Woodland N, Nassif N, Barbaro P, Bryant C, Hart D, Gibson J, Joshua D. Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia. 2016 Aug;30(8):1716-24. doi: 10.1038/leu.2016.84. Epub 2016 Apr 22. PubMed PMID: 27102208.
- Crighton G, Wood E, Scarborough R, Ho PJ, Bowden D. Haemoglobin disorders in Australia: where are we now and where will we be in the future? Intern Med J. 2016 Jul;46(7):770-9. doi: 10.1111/imj.13084. Review. PubMed PMID: 27040044.
- Bryant C, Fromm PD, Kupresanin F, Clark G, Lee K, Clarke C, Silveira PA, Suen H, Brown R, Newman E, Cunningham I, Ho PJ, Gibson J, Bradstock K, Joshua D, Hart DNj. A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset. Immunol Cell Biol. 2016 May;94(5):447-57. doi: 10.1038/icb.2015.116. Epub 2016 Jan 21. PubMed PMID: 26791160.
- Lee OL, Horvath N, Lee C, Joshua D, Ho J, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Talaulikar D, Brown R, Augustson B, Ling S, Jaksic W, Gibson J, Kalff A, Johnston A, Kalro A, Ward C, Prince HM, Zannettino A. Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Intern Med J. 2017 Aug;47(8):938-951. doi: 10.1111/imj.13502. PubMed PMID: 28782211.
- Lim ABM, Curley C, Fong CY, Bilmon I, Beligaswatte A, Purtill D, Getta B,
Johnston AM, Armytage T, Collins M, Mason K, Fielding K, Greenwood M, Gibson J,
Hertzberg M, Wright M, Lewis I, Moore J, Curtis D, Szer J, Kennedy G, Ritchie D. Acute myeloid leukaemia relapsing after allogeneic haematopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse. Intern Med J. 2017 Jun 19. doi: 10.1111/imj.13522. [Epub ahead of print] PubMed PMID: 28628276.
- Hsu J, Bryant C, Fromm PD, Papadimitrious M, Orellana D, Gasiorowski R, Joshua D, Brown R, Ho P, Iland H, Gibson J, Clark GJ, Hart DN: "CMRF-56 blood dendritic cell vaccination as consolidation therapy for acute myeloid leukaemia". Cytotherapy Volume 18, Issue 6, Supplement, Pages A1-A6, S1-S90 (June 2016), 22nd Annual ISCT Meeting, Singapore 2016.
- Iland H. Carl de Gruchy Oration: "Curing acute promyelocytic leukaemia - blunderbuss, vitamins, and a poison chaser". Keynote presentation at the HSANZ-ASTH-ANZSBT Annual Scientific Meeting, Melbourne, November 2016
- Iland H. Robert Pitney Travelling Fellow of HSANZ lecture: "Deconstructing normal karyotype AML". Presented in Brisbane, March 2016
- Iland H. Robert Pitney Travelling Fellow of HSANZ lecture: "Deconstructing normal karyotype AML". Presented in Sydney, May 2016
- Iland H. Robert Pitney Travelling Fellow of HSANZ lecture: "Deconstructing normal karyotype AML". Presented in Perth, May 2016
- Iland H. Robert Pitney Travelling Fellow of HSANZ lecture: "Deconstructing normal karyotype AML". Presented in Adelaide, July 2016
- Iland H. Robert Pitney Travelling Fellow of HSANZ lecture: "Deconstructing normal karyotype AML". Presented in Melbourne, August 2016
- Iland H. Robert Pitney Travelling Fellow of HSANZ lecture: "Deconstructing normal karyotype AML". Presented in Hobart, September 2016
- Iland H. NSW Oncology & Haematology Pharmacist Interest Group: "APL - update on treatment". May 2016
- Iland H. Westmead Hospital Haematology Department: "APL - update on treatment". June 2016
- Iland H. Royal Hobart Hospital Grand Rounds: "Arsenic, ATRA and acute promyelocytic leukaemia". Hobart, September 2016
||CIA: Hayley Suen, CIB: Joy Ho, CIC: John Gibson, CID: Douglas Joshua, CIF: Derek Hart
||Restoring the Function of Clonal Cytotoxic T cells in Multiple Myeloma to Develop Novel Therapies and Define the Antigenic Landscape
||CIA – Peter Croucher, CIB - Michelle McDonald, CIC – Tri Phan, CID – P. Joy Ho, CIE – Paul Baldock
||Anti-Sclerostin – a novel, dual action agent to treat multiple myeloma.
|AHCDO (Australian Haemophilia Centre Directors Organisation)
||Role of chromogenic FIX assay in (i) measuring FIX levels in haemophilia B patients to determine if there is a group of patients with discrepant results and (ii) comparison of this new assay with the one stage assay in measuring FIX levels in the spiked samples
Contact details for department
Head of Department: Prof P. Joy Ho (Director of Research)
Department/Unit: Institute of Haematology
Telephone: (02) 9515 8031
Facsimile: (02) 9515 6698